Ethyl 2-(5-bromopyridin-3-yl)acetate, 95.0%, 250mg

Z-Arg-OH.HCl, 95%, 100g

3-(Trifluoromethyl)phenyltrimethylammonium Hydroxide (5% in Methanol) [for Transesterification of Glyceride]25mL

4-isothiocyanato-2,1,3-benzothiadiazole, 250mg

2-Fluoro-3-pyridinecarboxylic acid, 98.0%, 25g

(R)-1-CYANOBUTAN-2-YL ((S)-1-(3-(3-(3-METHOXY-4-(OXAZOL-5-YL)PHENYL)UREIDO)PHENYL)ETHYL)CARBAMATE, 95%, 25mg

3'-carboethoxy-2-pyrrolidinomethyl benzophenone, 97.0%, 1g

N-methyl-N-{[1-(propan-2-yl)-1H-pyrazol-4-yl]methyl}piperidin-4-amine, 95.0%, 250mg

3',6'-DICHLOROSPIRO[BENZO[C][1,2]OXATHIOLE-3,9'-XANTHENE] 1,1-DIOXIDE, 95%, 250mg

bScope BS.1153-EPLPHi for phase contrast. Triocular with HWF 10x/20 mm eyepieces and quintuple revolver E-plan Phase IOS 10/20/S40 S100x

3,3,3-Trifluoro-2-(5-fluoro-1H-indol-3-yl)propanoic acid, 1g

3,4-Dimethylcyclohexanol, 97%, 10g

4-Chloromethyl-5,7-dimethyl-chromen-2-one, 95.0%, 250mg